Leukemia

Overall Survival and Progression-Free Survival Are Improved With Ibrutinib for del17p CLL

By

Ibrutinib treatment for chronic lymphocytic leukemia with the deletion of chromosome 17p (del17p CLL) increases the percentage of patients alive at 30 months over other therapies for del17p CLL.

Novel Antibody-Drug Conjugate Bridges Patients With Relapsed ALL to Stem Cell Transplant

Novel Antibody-Drug Conjugate Bridges Patients With Relapsed ALL to Stem Cell Transplant

By

In a randomized phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with ALL whose disease had relapsed following standard therapies, qualified for stem cell transplants after treatment with the drug.

Intensive Protocol Improves Survival for Adults with Acute Lymphoblastic Leukemia

Intensive Protocol Improves Survival for Adults with Acute Lymphoblastic Leukemia

By

Event-free survival for adult patients with ALL has improved from 40% to 73% with the implementation of the NOPHO ALL 2008 protocol in July 2008.

High Remission Rates Achieved With SGN-CD33A Combination in Older Patients With AML

High Remission Rates Achieved With SGN-CD33A Combination in Older Patients With AML

By

Deep and durable remissions were produced by the combination of SGN-CD33A and hypomethylating agents among patients with acute myeloid leukemia (AML).

Blinatumomab Improves Overall Survival in Acute Lymphoblastic Leukemia

By

Overall survival for patients with acute lymphoblastic leukemia (ALL) was nearly doubled to 7.8 months from 4.0 months by treating patients with blinatumomab compared with standard of care.

Higher Concentrations of Methotrexate for Pediatric Leukemia Affect Long-Term Cognitive Processes

Higher Concentrations of Methotrexate for Pediatric Leukemia Affect Long-Term Cognitive Processes

By

Pediatric patients with ALL treated with methotrexate can experience challenges with mental flexibility and organization compared with expectations from the general population.

Rituximab Maintenance Prolongs PFS in Patients With CLL

By

New research indicates that rituximab maintenance therapy can extend progression-free survival in patients with chronic lymphocytic leukemia achieving at least a partial response to induction therapy with rituximab and chemotherapy.

Anticancer Properties of Salicylic Acid and Diflunisal Revealed in Laboratory Experiments

Anticancer Properties of Salicylic Acid and Diflunisal Revealed in Laboratory Experiments

By

Researchers revealed a pathway in cell culture and mice by which salicylic acid decreases inflammation and by which salicylic acid and diflunisal decrease cancerous growth.

Prognostic Index Will Improve Clinical Practice Management of Patients With CLL and in Clinical Trials

By

An international consortium devised an international prognostic index for chronic lymphocytic leukemia (CLL-IPI) that combines genetic, biochemical, and clinical parameters into a prognostic model to enable more targeted management of patients with CLL.

Palbociclib Demonstrates Efficacy in Acute Myeloid Leukemia

By

The FLT3 tyrosine kinase is the most frequent mutation found in AML, and targeting CDK6 with palbociclib may be an effective strategy against AML.

FDA Accepts Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Priority Review

FDA Accepts Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Priority Review

By

The US FDA has granted Priority Review to ofatumumab used in combination with fludarabine and cyclophosphamide for the treatment of chronic lymphocytic leukemia.

Response to T-cell Immunotherapy Promising for Patients With Advanced B-cell Acute Lymphocytic Leukemia

Response to T-cell Immunotherapy Promising for Patients With Advanced B-cell Acute Lymphocytic Leukemia

By

Remission was achieved for 27 of 29 patients with advanced B cell acute lymphocytic leukemia (ALL) in an early phase trial of CAR T cells.

Antibody Therapy Reduces Numbers of Cancer Stem Cells in Patients With Multiple Myeloma

Antibody Therapy Reduces Numbers of Cancer Stem Cells in Patients With Multiple Myeloma

By

Cancer stem cells that drive tumor growth were halved by MEDI-551, an experimental antibody treatment for multiple myeloma, according to results of a small preliminary clinical trial.

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas

[Blood and Lymphatic Cancer: Targets and Therapy] This research examines the clinical trial data using idelalisib as monotherapy or in combination with rituximab for the treatment of indolent B-cell malignancies.

Targeted Therapies Suppress T-cell Response But Superagonist Can Overcome the Suppression

Targeted Therapies Suppress T-cell Response But Superagonist Can Overcome the Suppression

By

Dozens of targeted therapies, which are preferred as treatment over chemotherapy and surgery, suppress the activity of T cells that could help to fight tumors.

Efficacy of First-line Ponatinib in CP-CML Remains Unclear

Efficacy of First-line Ponatinib in CP-CML Remains Unclear

By

Ponatinib treatment was compared with imatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CP-CML).

Challenges faced in the treatment of acute lymphoblastic leukemia in adolescents and young adults

Challenges faced in the treatment of acute lymphoblastic leukemia in adolescents and young adults

[Clinical Oncology in Adolescents and Young Adults] This research reviews the outcomes with chemotherapy alone and with hematopoietic stem cell transplantation in acute lymphoblastic leukemia, and examines the challenges faced in determining the best therapy for the adolescents and young adult patient population.

Significant Reduction in Treatment Costs Are Anticipated With the Emergence of Generic TKI

Significant Reduction in Treatment Costs Are Anticipated With the Emergence of Generic TKI

By

With the January 2016 expiration of the patent on Gleevac, significant cost savings can be realized by insurance companies and patients. Just 15 years ago, Gleevac (imatinib) changed chronic myeloid leukemia (CML) from a fatal disease to a treatable illness.

Gut Bacteria Could Reduce GVHD in Patients Undergoing Bone Marrow Transplantation

Gut Bacteria Could Reduce GVHD in Patients Undergoing Bone Marrow Transplantation

By

A short-chain fatty acid made by bacteria in the gut could play an important role in GVHD after allogeneic bone marrow transplant in mice. In human patients who receive bone marrow transplants, GVHD can cause severe gut damage.

Research Results Bring Science One Step Closer to Creating Blood Stem Cells in the Laboratory

Research Results Bring Science One Step Closer to Creating Blood Stem Cells in the Laboratory

By

New research has shed light on how the blood is produced in the body, and this work, done in mice, moves science a step closer to manipulation of blood stem cell creation. This could reduce the need for bone marrow transplants, such as those needed by patients with cancer.

New Possible Treatment Addresses Specific Type of Leukemia

By

A subtype-specific weakness of T-cell acute lymphoblastic leukemia (T-ALL) could enable improved treatment, according to results from a a recent study using a mouse model.

Lymphocytosis Associated With Improved Survival in Dasatinib-treated Patients

Lymphocytosis Associated With Improved Survival in Dasatinib-treated Patients

By

Lymphocytosis is associated with higher response rates, significantly longer response durations, and improved overall survival.

Hair, Nail Abnormalities Common With Ibrutinib Therapy

Hair, Nail Abnormalities Common With Ibrutinib Therapy

By

Hair and nail abnormalities are commonly associated with the Bruton tyrosine kinase inhibitor ibrutinib.

Study Findings Show Possible Association Between PreLabor Cesarean Delivery and Risk for ALL in Young Children

By

The finding that prelabor cesarean delivery may have a correlation with acute lymphoblastic leukemia (ALL) may offer new targets for research into preventing cancer.

Combination Improves Anticancer Activity of 2 Agents in Acute Myeloid Leukemia

Combination Improves Anticancer Activity of 2 Agents in Acute Myeloid Leukemia

By

Combining birinapant with a p38 inhibitor is a promising therapeutic regimen for patients with acute myeloid leukemia (AML).

Patient Education Video an Effective Learning Tool, Provides Positive Experience

Patient Education Video an Effective Learning Tool, Provides Positive Experience

By

Video-based patient education tool is an effective adjunct to printed materials and one-on-one counseling on post HSCT.

Early Lineage T Cells Are Better for Immunotherapy in Pediatric Patients With ALL and Lymphoma

Early Lineage T Cells Are Better for Immunotherapy in Pediatric Patients With ALL and Lymphoma

By

Outcomes from a novel personalized cell therapy may be improved if specific subtypes of T cells are selected to attack diseases such as acute lymphoblastic leukemia and lymphoma.

Long-term Attention and Learning Deficits Persist After Chemotherapy for Pediatric Leukemia

By

Pediatric survivors of ALL treated only with chemotherapy remain at an increased risk for attention problems 2 years after treatment cessation.

Chromosomal Rearrangements Initiate High-risk Leukemia

By

Abnormal breakage and chromosomal rearrangement in white blood cells result in a particularly aggressive Philadelphia chromosome-like ALL, according to a new study.

Novel Technique Detects Persistent Leukemia in Patients Previously Thought to be in Remission

By

Persistent chronic myeloid leukemia in patients previously thought to be in remission can be detected with digital polymerase chain reaction.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs